{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:52:57Z","timestamp":1777675977202,"version":"3.51.4"},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.2169\/internalmedicine.9381-17","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T22:26:51Z","timestamp":1520548011000},"page":"2217-2221","source":"Crossref","is-referenced-by-count":36,"title":["Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis"],"prefix":"10.2169","volume":"57","author":[{"given":"Fumiaki","family":"Kudo","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutaka","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Jichi Medical University, Saitama Medical Center, Japan"},{"name":"Department of Clinical Oncology, Tokyo Medical University Hachioji Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Iwai","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Miwa","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Jichi Medical University, Saitama Medical Center, Japan"},{"name":"Department of Pulmonary Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yabe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Demitsu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Hagiwara","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Jichi Medical University, Saitama Medical Center, Japan"},{"name":"Department of Pulmonary Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Tokyo Medical University Hachioji Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627-1639, 2015.","DOI":"10.1056\/NEJMoa1507643"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292: 344-347, 1975.","DOI":"10.1056\/NEJM197502132920706"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 60: 12-25, 2016.","DOI":"10.1016\/j.ejca.2016.02.010"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sheik Ali S, Goddard AL, Luke JJ, et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 151: 195-199, 2015.","DOI":"10.1001\/jamadermatol.2014.2233"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Greenberg SA. Dermatomyositis and type 1 interferons. Curr Rheumatol 12: 198-203, 2010.","DOI":"10.1007\/s11926-010-0101-6"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2: 846-856, 2014.","DOI":"10.1158\/2326-6066.CIR-14-0040"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206: 3015-3029, 2009.","DOI":"10.1084\/jem.20090847"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Barnes BE, Mawr B. Dermatomyositis and malignancy. A review of the literature. Ann Intern Med 84: 68-76, 1976.","DOI":"10.7326\/0003-4819-84-1-68"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326: 363-367, 1992.","DOI":"10.1056\/NEJM199202063260602"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Albert ML, Darnell RB. Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer 4: 36-44, 2004.","DOI":"10.1038\/nrc1255"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1. Clin Cancer Res 23: 1920-1928, 2017.","DOI":"10.1158\/1078-0432.CCR-16-1741"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66: 1345-1349, 2007.","DOI":"10.1136\/ard.2006.068502"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev 11: 6-13, 2011.","DOI":"10.1016\/j.autrev.2011.06.007"},{"key":"14","unstructured":"14. Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35: 438-444, 2008."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Bohlmeyer TJ, Wu AH, Perryman MB. Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis. Rheum Dis Clin North Am 20: 845-856, 1994.","DOI":"10.1016\/S0889-857X(21)00069-7"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Gralla RJ, Spigel D, Bennett B, et al. PD1.01 (also presented as P 2.46): LCSS as a marker of treatment benefit with nivolumab vs docetaxel in pts with advanced non-squamous NSCLC from checkmate 057. J Thorac Oncol 11: S171, 2016.","DOI":"10.1016\/j.jtho.2016.08.009"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/15\/57_9381-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T18:14:27Z","timestamp":1660587267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/15\/57_9381-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":16,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9381-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,1]]}}}